Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Third-quarter FDA submission is expected for use of implantable cardiac defibrillators in treating nonsustained but inducible ventricular tachycardia. Data from the Multicenter Unsustained Tachycardia Trial (MUSTT) will support the filing, the firm says. Preliminary results reported March 8 at the American College of Cardiology conference from the 2,200-patient trial sponsored by NIH show that among patients whose therapy was guided by electrophysiological testing, ICD patients had "risk of arrhythmic death reduced by greater than 50%" compared to the group receiving anti-arrhythmic drugs or other conventional therapy," according to a same-day Medtronic release